The incidence of allergic rhinitis (AR) in Chinese adults was reported to be as high as 24.1% and 16.8% in children. The current symptomatic treatment has the disadvantage of poor efficacy and cannot change the natural course of the disease. Allergen immunotherapy (AIT) is the only causative treatment approved by the WHO, bringing a new option to patients with allergic diseases. The quality of allergen preparations is critical to the diagnosis and treatment of the disease, emphasizing the need for standardized preparations, and AIT treatment in the early stages of the disease may change the long-term progression of the disease. Recent studies have reported that the microbiome of patients with different efficacy of desensitization therapy is different and may be correlated with the clinical symptoms of patients, but no prospective studies have been reported.

Start Date20 Dec 2024

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

NCT06151938

/ Enrolling by invitationNot Applicable

A Prospective Observational Study Evaluating Relevance of Measurement Instruments in Assessing Effectiveness of ACARIZAX® in the Treatment of Moderate to Severe House Dust Mite Allergic Rhinitis With/Without Allergic Asthma in Chinese

The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR) with or without allergic asthma (AA) who are newly prescribed ACARIZAX® will be recruited for evaluation of the relevance of measurement instruments. The instruments referred to three patient-report scales of allergic rhinitis symptom and quality-of-life including the Daily symptom score (DSS), Standardised rhinoconjunctivitis quality-of-life questionnaire [RQLQ(S)], and Visual analogue scale (VAS). Other data will be collected to evaluate the effectiveness and safety of ACARIZAX® under real-world clinical practices.

Start Date21 Nov 2023

Sponsor / Collaborator

ALK-Abello A/S

NCT06509243

/ CompletedNot ApplicableIIT

Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis

Severe atopic dermatitis (AD) is a complex disease requiring systemic treatment. This study aimed to assess the effectiveness of combined therapy consisting of dupilumab and sublingual dust mite allergen immunotherapy (SLIT-HDM) in patients with severe AD and HDM allergies.
Methods: Patients diagnosed with severe AD were included in a randomized, placebo-controlled, double-blind 12-month trial; they received SLIT to HDM and/or dupilumab for 12 months and were compared to patients on cyclosporine. EASI, %BSA, and IsGA changes were analyzed in the different treatment arms from the beginning to the end of the 12th month. The secondary outcomes were the proportion of patients who achieved IsGA success and reduced medication scores.

Start Date10 Feb 2023

Sponsor / Collaborator

Medical University of Silesia

100 Clinical Results associated with House dust mites allergenics extract(ALK-Abello A/S)

100 Translational Medicine associated with House dust mites allergenics extract(ALK-Abello A/S)

100 Patents (Medical) associated with House dust mites allergenics extract(ALK-Abello A/S)

Literatures (Medical) associated with House dust mites allergenics extract(ALK-Abello A/S)

01 Jan 2025·PEDIATRIC PULMONOLOGY

Effect and mechanism of allergen‐specific immunotherapy on small airway dysfunction in children with asthma

Article

Author: Lin, Jie ; Dong, Wenfang ; Yin, Yong ; Wu, Jinhong ; Hong, Li ; Zhong, Wenwei ; Zhang, Lei ; Ying, Xiaolan ; Yang, Lin

Abstract:

Background:

The purpose of this study was to investigate the effectiveness of allergen‐specific immunotherapy (AIT) on small airway dysfunction (SAD) and the underlying mechanism with a special focus on basophils.

Methods:

Sixty‐five children with mild to moderate asthma who were under regular inhaled corticosteroid (ICS) treatment for more than 1 year but whose FEF75 remained below 65% of the predicted value and had positive results for serum Der p or Der f were enrolled. Children with asthma underwent house dust mite (HDM) subcutaneous immunotherapy (SCIT) treatment for 1 year. Clinical symptoms and lung function were evaluated every 3 months during HDM SCIT treatment. Basophil activation test (BAT) was carried out before and after HDM SCIT treatment. RNA sequencing was performed in isolated basophils from peripheral blood after 6 months of HDM SCIT treatment, followed by GO term and KEGG pathway enrichment analysis between patients with and without HDM SCIT treatment.

Results:

HDM AIT treatment ameliorated clinical symptoms while concurrently improved lung function parameters, such as FEV1/FVC, FEF75, FEF50 and MMEF (p < .05). It is worth noting that FEF75 values showed a highly significant, gradual and persistent increase (from 49.55 ± 1.27% at baseline to 71.89 ± 2.64% after 1 year of therapy) and 22 of 35 patients no longer had SAD after 1 year of treatment. BAT results revealed that AIT treatment significantly reduced basophil activity to the inhalant allergen mixtures containing HDM in vitro challenge from baseline. GO term and KEGG pathway enrichment analysis of basophils revealed that downregulated genes were mainly involved in immune cell activation, antigen presentation, and Th2 cell differentiation.

Conclusions:

Our study demonstrated that HDM AIT not only improved SAD related lung function parameters, but also reduced basophil activity. RNA sequencing revealed the inhibition of phagocytosis and the phagosome pathway in basophils which may affect the polarization of Th2 cell differentiation after HDM AIT.

01 Jan 2025·Lancet Regional Health-Europe

Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial

Article

Author: Gagnon, Remi ; Emeryk, Andrzej ; Schuster, Antje ; Caimmi, Davide ; Pfaar, Oliver ; Nolte, Hendrik ; Foss-Skiftesvik, Majken Hougaard ; Østerdal, Anne Sofie ; Mikler, Jan ; Novakova, Silviya

Background:

Allergic rhinitis/rhinoconjunctivitis (AR/C) induced by house dust mites (HDM) often begins in childhood and negatively impacts a child's quality of life. The daily burden can be further compounded by comorbid asthma. Allergen immunotherapy is the only available treatment targeting the underlying cause of allergic disease. Efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT)-tablet has been demonstrated in adults and adolescents with HDM AR/C with or without asthma, but data are lacking for younger children.

Methods:

Phase III, randomised, double-blind, placebo-controlled trial in younger children (5-11 years) with HDM AR/C with or without asthma. Eligible subjects were randomised 1:1 to SQ HDM SLIT-tablet or placebo for ∼1 year and had free access to AR/C symptom-relieving medications. The primary outcome was the total combined rhinitis score (TCRS) during the final 8 weeks of the treatment period (∼1 year). Secondary outcomes included the rhinitis daily symptom score (DSS) and medication score (DMS), the rhinoconjunctivitis total combined score (TCS), and the Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) score. Efficacy analyses were conducted on the full analysis set (observed cases). Asthma-related outcomes were also explored. The trial was registered on ClinicalTrials.gov: NCT04145219 and EudraCT: 2019-000560-22.

Findings:

A total of 1460 subjects were randomised to SQ HDM SLIT-tablet (n = 729) or placebo (n = 731). The primary outcome, TCRS, was statistically significantly different for SQ HDM SLIT-tablet (n = 693) versus placebo (n = 706), with an absolute difference of 1.0 (95% CI: 0.5, 1.4; p < 0.0001) corresponding to a relative reduction of 22.0% (95% CI: 12.0, 31.1). Key secondary outcomes (DSS, DMS, TCS, PRQLQ) showed statistically significant reductions in symptoms and medication use, and improved disease-related quality of life for SQ HDM SLIT-tablet versus placebo. Improvements in asthma symptoms and reduced asthma medication use indicated an additional effect of SQ HDM-SLIT tablet versus placebo. The SQ HDM SLIT-tablet showed a higher event rate for treatment-related adverse events (AEs) than placebo. Most events were of mild or moderate severity and few subjects discontinued due to AEs (2.5%).

Interpretation:

The trial confirmed the efficacy and safety of the SQ HDM SLIT-tablet for treating HDM AR/C in younger children (5-11 years) with or without asthma. The safety profile supports daily self-administration of the SQ HDM SLIT-tablet in children.

Funding:

ALK-Abellό, Hørsholm, Denmark.

12 Aug 2024·ACTA OTO-LARYNGOLOGICA

The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan

Article

Author: Masuno, Satoru

BACKGROUND:

Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases.

AIMS/OBJECTIVES:

To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that influence adherence and severe adverse reactions.

MATERIAL AND METHODS:

In total, 174 patients aged 12 years or older who started sublingual immunotherapy for Japanese cedar pollinosis (n = 72), house dust mite allergy (n = 55), or both (n = 47) between May 2017 and June 2018. Patient age, sex, type of pharmacotherapy used, adverse reactions, blood test results, and duration of continuous treatment were investigated.

RESULTS:

The three-year treatment continuation rate was 40.8%. Adverse reaction rates were 12.6% for cedar pollinosis and 40.2% for house dust mite allergy. Patients with dose reductions due to severe reactions had lower first-year continuation rates. In the MITICURE^® group, patients with severe reactions had significantly higher serum total IgE levels. Severe reactions were more common in MITICURE^® patients with seven or more positive antigen types.

CONCLUSIONS AND SIGNIFICANCE:

Severe adverse reactions reduced early adherence.

News (Medical) associated with House dust mites allergenics extract(ALK-Abello A/S)

27 Feb 2025

·ir.alk.net

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reliance on symptomatic medication. The FDA approval is an important step in ALK’s efforts to make all its respiratory tablets available for all age groups – children, adolescents, and adults - in all relevant markets. ALK’s Executive Vice President of R&D, Henriette Mersebach (MD), says: “I’m very pleased with the FDA approval of ODACTRA® in young children, as this will enable us to provide an important and potentially life-changing treatment option for children who experience troublesome symptoms and impaired quality of life related to their allergic disease. Building upon our longstanding commitment to developing evidence-based innovative medicines, we now look forward to making ODACTRA® available for children through our US prescriber networks and through commercial and government markets.” The data that formed the basis for the approval includes results from the largest-ever paediatric AIT Phase 3 clinical trial, MT-12, which involved 1,460 children in North America and Europe. The trial demonstrated efficacy and safety of the treatment in children, and the results were recently published in the reputable scientific journal, The Lancet Regional Health – Europe. Globally, it is estimated that more than ten million children, aged five to 11, have uncontrolled respiratory allergies and the number is growing. House dust mites are a common cause of allergy and closely linked to asthma. ALK’s house dust mite allergy tablet is marketed as ODACTRA® in USA, as ACARIZAX® in Europe and several international markets, as MITICURE™ in Japan, and as Sensimune™ in India. Until now, the tablet has been approved for use in young children in Europe and in Japan. A corresponding regulatory review is currently ongoing in Canada. Furthermore, a separate regulatory review of ALK’s tree tablet ITULAZAX® also for use in children is currently ongoing in Europe and Canada. These reviews are expected to complete in 2025, after which all ALK’s tablets will be approved for children, adolescents, and adults in relevant markets. The approval is not expected to affect ALK’s financial outlook for 2025. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. Attachment Company release_04_25UK_270225_ODACTRA_approval_children

ImmunotherapyDrug ApprovalPhase 3Clinical Result

19 Feb 2025

·www.globenewswire.com

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent the best results in the history of the company. ALK expects to continue its growth trajectory and earnings improvement in 2025. Q4 2024 highlights (Comparative figures are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated) Revenue increased by 11% to DKK 1,499 million (1,345) on continued strong performance in Europe. As anticipated, North America and International markets did not contribute to growth in this quarter. Tablet sales increased by 17% to DKK 795 million (677). Europe remained the key contributor with 32% growth, reflecting a continued inflow of new patients and improved pricing. Combined SCIT and SLIT-drops sales increased by 5% to DKK 552 million (522), while sales of Other products increased by 2% to DKK 152 million (146). Operating profit (EBIT) improved modestly to DKK 205 million (194) as ALK advanced investments in selected R&D projects and Sales & Marketing initiatives. Total costs also included one-off costs related to the in-licensing of neffy®, as well as DKK 26 million in optimisation costs, primarily in China.Major milestones achieved: the in-licensing of neffy® adrenaline nasal spray, paediatric European approval of ACARIZAX® house dust mite tablet, and positive clinical results with peanut tablet. Growth GrowthDKKmQ4 2024l.c.r.c.FY 2024l.c.r.c.Revenue1,49911%11%5,53715%15%EBIT2056%6%1,09165%64%EBIT margin 14% 20% l.c.: local currency; r.c.: reported currency Full-year 2024 highlights Revenue increased by 15% to DKK 5,537 million (4,824) on growth in all product lines. Tablet sales increased by 24% to DKK 2,851 million (2,296) on growth in all sales regions. European tablet sales sustained momentum with 31% growth, driven by higher volumes and improved pricing. Sales of SCIT and SLIT-drops increased by 6% to DKK 2,052 (1,939) on solid performance in Europe. Sales of Other products increased by 7% to DKK 634 million (589), driven by Jext®. EBIT was DKK 1,091 million (666) on higher sales, gross margin improvements, and modest cost increases, despite DKK 75 (0) million in one-off optimisation costs. The margin was 20% (14). Free cash flow was DKK minus 204 million (positive at 292), and excluding the upfront payment related to the neffy® license agreement, free cash flow ended better than expected and increased to DKK 790 million, driven by improved earnings, lower CAPEX, and changes to working capital. 2025 financial outlook Revenue is expected to grow by 9 -13% primarily on volume-driven growth across sales regions and product groups. Tablet remain key to growth. The EBIT margin is expected to improve by 5 percentage points to around 25%, driven by revenue growth, improving gross margin, and optimisations. ALK's CEO Peter Halling says: “2024 was a remarkable year in which we delivered considerably better results than we originally anticipated. We established a new strategic framework for ALK’s long-term development and are expanding our addressable markets in respiratory allergy by adding new patient groups – especially children – and new markets. Efforts are also well underway to build new revenue streams in anaphylaxis, food allergies, and other allergic conditions with high unmet needs”. The comprehensive annual report continues on the subsequent pages. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 WebcastToday, ALK is hosting a conference call for analysts and investors at 13.30pm (CET) at which Management will review the financial results and the outlook. The conference call will be webcast live on https://ir.alk.net where the accompanying presentation will be available. To register for the conference call, please use this link and follow the registration instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. Attachments ALK_Annual report 2024_Company release_01_2025 alk-2024-12-31-en

Financial StatementImmunotherapyLicense out/in

30 Jan 2025

·www.globenewswire.com

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to severe house dust mite allergic rhinitis in adults and adolescents. The recommendation paves the way for patients to gain access to ACARIZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland, now making it eligible for general reimbursement. ACARIZAX® is the first sublingual allergy immunotherapy (AIT) product to be assessed and recommended by NICE, and the treatment will be the first of its kind to become widely available through the National Health Service (NHS) systems. The UK is currently one of the few European markets, where ALK’s allergy tablets are authorised without adequate public reimbursement. Additionally, there is a significant underutilisation of AIT in the UK compared to other European countries. ALK’s Executive Vice President of Commercial Operations, Søren Niegel, says: “Today’s news marks a milestone for ALK. NICE’s methodologies and guidelines are widely regarded as the gold standard, and we are proud to become the first and only company to make sublingual allergy immunotherapy tablets widely accessible in the United Kingdom for the benefit of the many patients whose lives are profoundly impacted by allergy.” Allergic rhinitis disease is a prevalent condition in the UK, affecting 26% of adults. Among these, house dust mite is the most common airborne allergy, affecting approximately half of those living with allergic rhinitis disease – upwards of 5 million people in the UK. Despite a range of symptomatic treatment options, approximately one million people still live with debilitating and uncontrolled symptoms. NICE conducts reviews to assess the clinical benefits and cost-effectiveness of healthcare interventions, treatments, and technologies. The institute published a Final Draft Guidance on 30 January 2025, appraising the clinical benefits and cost-effectiveness of ACARIZAX® in the treatment of uncontrolled house dust mite allergy. NICE is expected to publish a Final Guidance in March, after which the NHS systems in England, Wales and Northern Ireland are required to implement ACARIZAX® in the treatment practices. ALK also plans to soon submit a similar application for a NICE review of its sublingual tree tablet, ITULAZAX®. Submissions will also be made to extend the approvals for ACARIZAX® and ITULAZAX® to include children. ALK’s current business in the UK mainly focuses on anaphylaxis (treatment of severe allergic reactions) with the adrenaline pen Jext® on the market and the nasal spray EURneffy® due for launch later this year, pending regulatory approval. AIT tablet sales are currently modest, but ALK expects the combination of its anaphylaxis treatments and the tablets to create long-term synergies in parallel with an expanded infrastructure and as more patients become aware of these treatment options. The NICE approval is not expected to affect ALK’s revenue growth in 2025. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. Attachment InvestorNews_30Jan25_ACARIZAX recommended by NICE

ImmunotherapyDrug Approval

100 Deals associated with House dust mites allergenics extract(ALK-Abello A/S)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V01AA03	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Asthma	KR	Abbott Laboratories	02 Jan 2018
Conjunctivitis	CA	Merck Canada, Inc.	04 May 2017
Epilepsy, Idiopathic Generalized	CA	Merck Canada, Inc.	04 May 2017
House dust mite allergy	CA	Merck Canada, Inc.	04 May 2017
Rhinitis, Allergic	CH	ALK-Abello A/S	24 Aug 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Allergic rhinoconjunctivitis	Phase 3	CN	ALK-Abello A/S	06 Nov 2019
Allergic rhinoconjunctivitis	Phase 3	CN	Danish Alkai--Abeyo Company Beijing Representative Office	06 Nov 2019
Allergic asthma	Phase 3	BY	Abbott Laboratories	01 Oct 2015
Allergic asthma	Phase 3	RU	Abbott Laboratories	01 Oct 2015
Anaphylaxis	Phase 3	BY	Abbott Laboratories	01 Oct 2015
Anaphylaxis	Phase 3	RU	Abbott Laboratories	01 Oct 2015
allergic rhinitis due to dust mite	Phase 3	-	Merck Sharp & Dohme Corp.	01 Jan 2013
allergic rhinitis due to dust mite	Phase 3	-	ALK-Abello A/S	01 Jan 2013
Rhinitis, Allergic, Perennial	Phase 3	-	Merck Sharp & Dohme Corp.	01 Jan 2013
Rhinitis, Allergic, Perennial	Phase 3	-	ALK-Abello A/S	01 Jan 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04145219 (MT-12, Literature) Manual	Phase 3	allergic rhinitis with asthma	1,460	SQ HDM SLIT	dgrloohiup(lchcmsvmzq): Difference = 1.0 (95% CI, 0.5 - 1.4), P-Value = < 0.0001 View more	Positive	26 Nov 2024
				Placebo
NCT04145219 (MATIC \| phase 3 \| MT-12, CTgov)	Phase 3	Rhinoconjunctivitis \| allergic rhinitis due to dust mite \| Asthma	1,460	HDM (HDM SLIT-tablet (12 SQ-HDM))	amxlhaevdj(wjkkuyacxp) = gvdyurtsez duzfrwndao (kmpdeacstr, xjjsxtuxmn - nszhkadheh) View more	-	12 Jun 2024
				Placebo (Placebo SLIT-tablet)	amxlhaevdj(wjkkuyacxp) = idbxoojjva duzfrwndao (kmpdeacstr, eiqdugohmy - nbdbywbefc) View more
NCT03654976 (MAPIT, CTgov)	Phase 3	Rhinitis, Allergic \| Allergic asthma \| House dust mite allergy	533	HDM (HDM SLIT-tablet (12 SQ-HDM))	hxhnrqissb(jzxhwsckkh) = mqftgewbpn mygdaysnto (guhipdaiak, gbdgzvnoag - yovndcxacs) View more	-	19 Oct 2023
				Placebo (Placebo SLIT-tablet)	hxhnrqissb(jzxhwsckkh) = tqjaldaqgo mygdaysnto (guhipdaiak, wiphtrsmow - jilksomgqt) View more
NCT04541004 (AMASE, CTgov)	Phase 3	Rhinoconjunctivitis \| Asthma \| Rhinitis, Allergic	253	HDM SLIT-tablet	gpzqppbddx(uqvktruzbq) = ttxsqpkmyc dxkasfvwnz (mzchwcawdp, qiuzpphjke - zibufhcfks) View more	-	03 Jul 2023
NCT02596321 (CTgov)	Phase 3	Rhinitis, Allergic \| Allergic asthma \| Anaphylaxis	112	Mitizax (Mitizax ALK HDM Tablet)	nnmbwzggan(gbgtfagoqd) = ojotoenftx xcshtocedm (inihzffxep, aqxmknzsba - cdeufjvfqr) View more	-	18 Dec 2017
				Placebo (Placebo Tablet)	nnmbwzggan(gbgtfagoqd) = rfnamerftw xcshtocedm (inihzffxep, nyjpnqwyaf - vpgwjggael) View more
NCT01700192 (P05607 \| trial A, CTgov)	Phase 3	Rhinoconjunctivitis \| allergic rhinitis due to dust mite \| Asthma ... View more	1,482	MK-8237 tablets (MK-8237)	yuyoxvmvns(npevdljdlb) = hfxlgaahoz keahhzrrjo (fkjkbwqpei, pmblrzjnom - dshaudzyan) View more	-	03 Mar 2017
				Placebo tablets (Placebo)	yuyoxvmvns(npevdljdlb) = oyuazfejkq keahhzrrjo (fkjkbwqpei, pobmszzpmp - qzukfwwibc) View more
NCT01852825 (8237-009, CTgov)	Phase 1	allergic rhinitis due to dust mite \| Rhinoconjunctivitis	26	MK-8237 (NAC + MK-8237 (Part 2))	nmtjzhplig(fttekfijdq) = ufusowszgp mxhivbabqc (sxoxfaioqk, lpldlbfaxt - cyqtadotby) View more	-	13 Feb 2017
				Placebo+NAC (NAC + Placebo (Part 2))	nmtjzhplig(fttekfijdq) = wyiyotklew mxhivbabqc (sxoxfaioqk, lmipsoypdx - xmjqtzavda) View more
NCT01678807 (8237-008 \| MK-8237-008, CTgov)	Phase 1	Rhinitis, Allergic, Perennial \| House dust mite allergy	195	MK-8237 12 DU (MK-8237 12 DU)	bbldjupmxa(rwfpwpopal) = zckaapcern gswyfrciqh (eyutyrhvdw, vblajmtmus - asgadtiros) View more	-	13 Feb 2017
				MK-8237 6 DU (MK-8237 6 DU)	bbldjupmxa(rwfpwpopal) = nxwgfdtcby gswyfrciqh (eyutyrhvdw, ymiszcwqot - eemngertkk) View more
NCT01644617 (P07627 \| 8237-003, CTgov)	Phase 2	Rhinoconjunctivitis \| Rhinitis, Allergic, Perennial \| House dust mite allergy	124	MK-8237 12 DU (MK-8237 12 DU)	exhwsddbnm(hteyhcyqby) = dlfnncywyj zimcxkpecj (vgombhatpb, uugygnjqkg - finkifnygb) View more	-	13 Feb 2017
				Placebo (Placebo)	exhwsddbnm(hteyhcyqby) = xckjhpnwmt zimcxkpecj (vgombhatpb, hrbnqgjqxu - wmgwwsxajm) View more
NCT01700192 (Pubmed \| J Allergy Clin Immunol) Manual	Phase 3	Asthma \| Allergic rhinoconjunctivitis	1,482	MK-8237	ocwwdrmdfu(wdoggpiced) = oudldacesn fonuamdadk (vnhfpbzorm, 10 - 25) View more	Positive	01 Dec 2016
				Placebo	-

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

House dust mites allergenics extract(ALK-Abello A/S)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation